Reports Q2 revenue $21.1M vs.$16.6M last year.As of June 30, 2023, cash, cash equivalents and marketable securities totaled $55.3 million. This figure does not include proceeds from the recent $120 million private placement of ordinary shares and pre-funded warrants.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on URGN:
- URGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ‘Opportunities Outweigh Risks’: Oppenheimer Sees at Least 60% Gains in These 2 Stocks
- UroGen Pharma price target raised to $54 from $23 at H.C. Wainwright
- UroGen Pharma price target raised to $52 from $47 at Ladenburg
- UroGen Pharma price target raised to $33 from $22 at Oppenheimer
